Immupharma PLC Grant of Share Options
April 19 2024 - 2:00AM
RNS Regulatory News
RNS Number : 2334L
Immupharma PLC
19 April 2024
19 April 2024
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Grant of
Share Options
ImmuPharma PLC (LSE:IMM), the
specialist drug discovery and development company, announces the
grant of unapproved share options over ordinary shares of 1 penny
each to directors as follows.
Lisa
Baderoon
3,000,000 share options (exercise price: 2.24p)
Laurence
Reilly
2,000,000 share options (exercise price: 2.24p)
Share Option Period: All Share
Options are valid for 10 years from the date of issue and will vest
three years from the date of issue.
ENDS
For further information please
contact:
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 203 650 3650
+44 (0) 1483 413500
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, Lupuzorâ„¢, is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases
that share the same autophagy mechanism of action.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
Notification and public disclosure
of transactions by persons discharging managerial responsibilities
and persons closely associated with them.
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Lisa Baderoon
|
2
|
Reason for the
notification
|
a)
|
Position/status
|
Non-Executive Director
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
3
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
a)
|
Name
|
ImmuPharma PLC
|
b)
|
LEI
|
213800VZKGHXC7VUS895
|
4
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010
|
b)
|
Nature of the transaction
|
Grant of share options over new Ordinary
Shares
|
c)
|
Price(s) and volume(s)
|
Exercise
Price
|
Volume
|
2.24 pence
|
3,000,000
|
|
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
|
e)
|
Date of the transaction
|
18
April 2024
|
f)
|
Place of the transaction
|
n/a
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
Laurence Reilly
|
2
|
Reason for the
notification
|
a)
|
Position/status
|
Senior Non-Executive Director
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
3
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
a)
|
Name
|
ImmuPharma PLC
|
b)
|
LEI
|
213800VZKGHXC7VUS895
|
4
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010
|
b)
|
Nature of the transaction
|
Grant of share options over new Ordinary
Shares
|
c)
|
Price(s) and volume(s)
|
Exercise
Price
|
Volume
|
2.24 pence
|
2,000,000
|
|
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
|
e)
|
Date of the transaction
|
18
April 2024
|
f)
|
Place of the transaction
|
n/a
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHZZGMDVRRGDZM
Immupharma (LSE:IMM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Nov 2023 to Nov 2024